氨磷汀对淋巴瘤化疗病人重要脏器保护作用临床观察

目的 观察氨磷汀（阿米福汀）对淋巴瘤化疗病人重要脏器保护作用及药物不良反应和安全性。方法 16例恶性淋巴瘤病人均接受单纯化疗（对照组）及化疗加阿米福汀（治疗组）两种方案治疗，作自身前后对照研究。化疗前后监测肝功能、肾功能、心功能及血常规、血钙浓度。结果 化疗相关肝功能损害对照组出现11例，治疗组出现2例（P〈0．01）；肾功能损害仅见对照组出现4例，心功能损害仅见对照组出现1例，治疗组未出现心肾功能损害（P〉0．05）；化疗后发生粒细胞缺乏症对照组11例，治疗组4例（P〈0.01）。结论 阿米福汀能明显减少化疗相关肝功能损害的发生，减少化疗后粒细胞缺乏症的发生。阿米福汀不良反应少见，主要是恶心呕吐、短暂的低血钙症。

Clinical observation for Amifostine in protection of major organs from lymphadenoma chemotherapy patients

OBJECTIVE To evaluate Amifostine's effect on protecting major organs from lymphadenoma chemotherapy patients and its adverse reactions and safety.METHOD 16 patients were treated by two kinds of treatments for self contrast and research,one was chemotherapy(control group),the other was chemotherapy plus Amifostine(treatment group).Indexes such as liver function,kindney function,heart function,blood routin and blood calcium were mentioned before or after chemotherapy.RESULTS Liver function damage occurs in 2 patients from treatment group,and in 11 patients from control group(P<0.01).Kindney function damage problem was found in 4(control group).Heart function damage problem was found in 1(control group).No kindney heart problem found in treatment group(P>0.05).Agnanulaytosis was found in 11(control group),in 4(treatment group)(P<0.01).CONCLUSION Amifostine can apparently reduce the damage of liver function and agranulaytosis.The main side effects of Amifostine are nause,vomiting and hypocalcemia.